Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine-induced phBOLD and TS-134/XT in Healthy Volunteers
NCT05401227Phase 1Recruiting
- Sponsor
- New York State Psychiatric Institute
- Start
- Oct 2022
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of TS-134 in schizophrenia (6 arms), sponsored by New York State Psychiatric Institute. Primary endpoints: Final PharmacoBOLD signals in pre-specified ROIs at Day 4 and Brief Psychiatric Rating Scale at Day 4. Started Oct 2022; status: recruiting.
02
Drugs
TS-134
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05401227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05401227.